home / stock / phio / phio news

PHIO News and Press, Phio Pharmaceuticals Corp. From 04/11/24

Stock Information
Company Name: Phio Pharmaceuticals Corp.
Stock Symbol: PHIO
Market: NASDAQ
Website: phiopharma.com
Menu
PHIO PHIO Quote PHIO Short PHIO News PHIO Articles PHIO Message Board
Get PHIO Alerts

News, Short Squeeze, Breakout and More Instantly...
PHIO - Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is ...
PHIO - National Spotlight Features Phio's Innovative RNAi Technology Platform

—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL&#x...

PHIO - Phio Pharmaceuticals GAAP EPS of -$5.20

2024-04-02 07:39:07 ET More on Phio Pharmaceuticals Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceuticals Read the full article on Seeking Alpha For...

PHIO - Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments, extending Phio’s expertise in dermatological treatm...
PHIO - Expected US Company Earnings on Wednesday, March 27th, 2024

Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...

PHIO - PHIO and MGRM among healthcare movers

2024-03-21 10:12:15 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

PHIO - Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

MARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is ...
PHIO - Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the ad...

PHIO - Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that t...

PHIO - Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

-- New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is desig...
Previous 10 Next 10